ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011

Transcription

1 ProMetic Life Sciences Inc. Biotech Showcase San Francisco January,

2 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking statements about ProMetic s objectives, strategies and businesses that involve risks and uncertainties. These statements are forward-looking because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forwardlooking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic s Annual Information Form for the year ended December 31, 2009, under the heading Risk Factors. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise. Copyright notice The information contained in this presentation (including names, images, logos and descriptions portraying ProMetic's products and/or services) is the property of ProMetic Life Sciences Inc., of its divisions and / or of its subsidiaries ( ProMetic ) and is protected by copyright, patent and trademark law and / or other intellectual property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including printing and photocopying, or by any information storage or retrieval system without prior permission in writing from ProMetic. Disclaimer ProMetic reserves the right to make improvements, corrections and/or changes to this presentation at any time 2

3 ProMetic - 4 Opportunities : 1 Company 3

4 ProMetic - Background PLI:TSX Formed in 1995, IPO in 1998 ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics 100 personnel in various locations worldwide: UK, USA, Canada Strategic alliances / licensing agreements with >35 companies and institutions 2 subsidiaries originally started as joint ventures with American Red Cross Supplier of choice to major pharmaceutical companies 4

5 Commercial applications successfully developed from core technologies Extracorporeal Devices Diagnostics Coatings/ ELISA plates Proprietary Drugs Medical Devices Laboratory Purification Kits HTS / Lab Technologies Process Chromatography Peptide Synthesis Prion Technologies / Contract Research Membranes/ filters 5

6 Investment Case 6

7 Why Invest In ProMetic? Because we are different Not all cash-burn. Company has an established revenue stream from multiple industry leaders. Company moving towards EBITDA breakeven without revenue from key value drivers. These value drivers are close to delivering material revenues. Any one of these value drivers can significantly increase share price beyond current value. Technology with proven track-record. Strong management able to steer through tough market conditions whilst building value. Company now set-up for Multiple shots at the goal.

8 PLI:TSX Value Drivers ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Expanding client base Continue revenue growth & profitability Clients products regulatory approval = catalysts for growth 8

9 PLI:TSX Value Drivers ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Adoption of prion filters by European governments Technology for Safer biopharmaceuticals 9

10 PLI:TSX Value Drivers ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Best-in-class biosimilars to access $9 B market Development partnered with established companies Cheaper to manufacture products (higher yield / lower cost) Licensing for multiple markets 10

11 PLI:TSX Value Drivers ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Multiple Licensing Deals Fibrosis, Cancer, Anemia Huge unsatisfied market Affecting > 100 Million patients worldwide 11

12 PLI:TSX How could value drivers impact share price? ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Target Valuation > $ 500 Million Target valuation > $500 Million Target valuation > $ 1 B Target valuation > $ 10 B Profitable since 2007 Possible Share Price impact: $1 - $1.50 Sales expected to commence in 2011 Possible Share Price impact: Development revenue & partnering in 2011 Possible Share Price impact Partnering deals in 2011 with $, milestones and royalties Possible Share Price impact $1 - $1.50 $2 - $3 >$5 12

13 Description of Business Units 13

14 PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics ProMetic s core technologies create long term recurring revenue with Proprietary adsorbent embedded in partners manufacturing processes. 12 FDA / EMEA approved products > 25 other products under development Business unit profitable since

15 PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Cases of CJD continue to increase in the UK P-Capt prion capture device is CE Marked Expert panel recommends UK Department of Health to implement Number Cases Sporadic CJD Variant CJD Other Prion Diseases UK government independent studies validate safety and efficacy of P-Capt 15

16 P-Capt filter 2.6 m blood donations per year in the UK & Ireland 16

17 PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics US$ 9 Billion market Most plasma fractionators rely on Cohn process established 60 years ago for albumin Most high value therapeutics that followed have low yield Prometic s process co-developed with the American Red Cross has better extraction yield and provides for higher purity, removal of prions > IVIG $ 4 B yield 40% > vwf-fviii $ 600 M yield 250% > Hyperimmunes $ 1 B yield 40% 1. SIGNIFICANTLY lowers Manufacturing Cost 2. SAFER therapeutics 3. BEST-IN-CLASS BioSimilars 17

18 Turn-key process for Best-in-class Therapeutics derived from plasma Human plasma - pooled for batch process cgmp Manufacturing process Pure Bulk Active Ingredient Finished Dosage form Protein extraction Prionremoval 18

19 Turn-key process for Best-in-class BioSimilars Largest BioPham Co in China Supplies 80% of vaccines, 45% blood Progressing toward scaling up Targets >1.3 Million liters of plasma 7 products derived from plasma OctaplassLG approved in Germany Pending approval in restof Europe & USA Developing several products Leverage best yield best safety / purity profile Human plasma - pooled for batch process Protein extraction Prionremoval Developing hyperimmunes Developing hyperimmunes & other proteins prion depleted 19

20 PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Strong intellectual property position Orally active, small synthetic molecules First-in-class, novel mechanism of action Validated receptors Very high safety profile Proof of concepts validated Targets unmet medical needs Inflammation Fibrosis Autoimmune disease Oncology Anemia 20

21 Chronic Kidney Disease (CKD) 26 million (or 1 in 9) Americans have CKD and millions more at increased risk ` Heart disease is the major cause of death for all people with CKD Hypertension Hypertension causes CKD CKD causes hypertension Anemia Cardiovascular Complications Risk Factors Diabetes nephropathy CKD End Stage Renal Disease Dialysis Diabetes Fibrosis = progression of CKD to kidney failure

22 ProMetic Drug Candidates beneficial effects in patients with Chronic Kidney Disease (CKD) Risk factors PBI-4419 PBI-4050 Anemia Cardiovascular Complications Hypertension Risk Factors Diabetes nephropathy CKD End Stage Renal Disease Dialysis Diabetes 22

23 Proprietary drugs reduce disease progression The kidneys from non treated animals show deposits of collagen at the base of the glomerulus and all the surrounding tissue. The kidney function is greatly reduced as a result of necrosis. Treated animals have normal kidneys with no fibrosis and necrosis. Photomicrographs (100X) of renal tissue from 5/6-Nephrectomized animals 23

24 Proprietary drugs prevent cardiac fibrosis - reduce collagen deposition (Fibrosis collagen coloured in blue) Non treated Treated 24

25 Provides Medical & Economical Benefits Prevents and or delays fibrotic process in kidneys & heart Delay or prevent diabetic induced nephropathy & cardiomyopathy Anti- Fibrotic Agents Delay progression of CKD to Kidney failure Delay need for hemodialysis Reduce need for blood transfusion Reduce need for organ transplantation Protect transplanted kidney Orally active drugs

26 Partnering strategies for drug candidates Product Target indications Patent Proof of concept Tox GMP scale-up GLP tox Clinical trials / IND PBI-1402 Anemia PBI-1402 Oncology Allist - China PBI-1402 Analogues e.g., PBI- 4050, PBI PBI-1308 PBI-1737 Others Fibrosis Autoimmune diseases Autoimmune diseases To be announced Allist - China 26

27 Strategic Agreement with Allist Pharmaceuticals, Inc. Allist to develop and commercialize ProMetic's drug candidates PBI-1402 and PBI-4419 in China. Allist to fund PBI-1402 and PBI-4419 in return for exclusive commercial rights for the Chinese market. ProMetic retains rights to data for other markets representing savings of over US $10M in future development costs. US$ 59 M in milestone payments to ProMetic + royalties. This means PBI-4419 is expected to be in Phase Ib/II clinical trial in 2011 PBI-1402 phase II clinical program will be expanded in

28 Catalysts for Growth 28

29 In Summary - Catalysts PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Allist $10 M investment in the development program to advance PBI-compounds in the clinic Other partnerships to provide $ & further advance the drugs in the clinics 29

30 In Summary - Catalysts PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics New agreements driving in $ New strategic opportunity to increase value Continue advancement of programs with existing partners WIBP (China) program expanding to cgmp manufacturing 30

31 In Summary - Catalysts PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Expect adoption of P-Capt in the UK in 2011 driving $ Expect adoption of P-Capt in other countries New commercial applications with industrial partners 31

32 In Summary - Catalysts PLI:TSX ProMetic UK (PBL) Bioseparation PRDT Prion removal technology ProMetic USA (PBT) Plasma proteins ProMetic BioScience (PBI) Canada Therapeutics Expanding client base Continue revenue growth & profitability Clients products achieving regulatory approval New Strategic Alliances 32

33 A plan that leverages our core technologies beyond 2011 Therapeutics Value added chain BioSeparation Medical devices / pathogen reduction Best-in-Class plasma derived BioSimilars 33

34 Strengthening the Balance Sheet Debt provided by long-term stakeholders whose interests are aligned with ProMetic s success; Efforts underway to favourably reorganise terms of existing debt to improve liquidity; Closing value driving deals will strengthen balance sheet.

35 In Summary - Why Invest In ProMetic? Because we are different Not all cash-burn. Company has an established revenue stream, from multiple industry leaders. Company moving towards EBITDA breakeven without revenue from key value drivers. These value drivers are close to delivering material revenues. Any one of these value drivers can significantly increase share price beyond current value. Technology with proven track-record. Strong management able to steer through tough market conditions whilst building value. Company now set-up for Multiple shots at the goal.

36 Thank you